Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Treace Medical Concepts, Inc. (TMCI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed medical technology company focused on bunion and related midfoot deformities, Treace uses these filings to report financial results, material agreements, governance changes and risk factors relevant to TMCI stockholders.
Investors can review annual reports on Form 10‑K for a detailed discussion of Treace’s business, including its Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, minimally invasive Nanoplasty and Percuplasty systems, SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants, IntelliGuide patient specific technology, and associated risk factors and market considerations. Quarterly reports on Form 10‑Q provide interim financial statements, management’s discussion and analysis and updates on operations and liquidity.
Current reports on Form 8‑K capture specific material events, such as the entry into new senior secured term loan and revolving credit agreements, repayment and termination of prior credit facilities, earnings releases for quarterly periods and changes in the composition or roles of the board of directors. These filings outline key terms of financing arrangements, including collateral, interest rates, covenants and potential implications for dividend payments.
Users can also monitor proxy statements and related materials for information on governance, board structure and executive compensation, as well as Section 16 filings such as Form 4 for reports of insider transactions in TMCI shares. Stock Titan’s platform pairs these documents with AI‑powered summaries that explain complex sections, highlight notable items and help readers quickly understand how new filings may relate to Treace’s bunion‑focused business, financial condition and capital structure.
With real‑time updates from EDGAR and structured access to key forms, this page serves as a central resource for analyzing TMCI’s regulatory history and ongoing disclosure record.
Treace Medical Concepts, Inc. Chief Financial Officer reports an insider stock transaction. On 01/10/2026, Mark Hair reported an "F" code transaction involving 8,719 shares of common stock at a reported price of $0 per share. Following this transaction, he beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct form. A noted portion of this position consists of 398,009 restricted stock units, which typically represent share-based awards that may settle in stock over time.
Treace Medical Concepts, Inc. officer Elder Scot Michael, Chief Legal & Compliance Officer and Corporate Secretary, reported a transaction in company common stock dated 01/10/2026. A transaction coded "F" involved 4,544 shares at a reported price of $0 per share, after which he beneficially owned 543,737 common shares. This beneficial ownership figure includes 410,845 restricted stock units.
Treace Medical Concepts, Inc. reported an insider ownership update for Chief Executive Officer and director John T. Treace. On January 10, 2026, a Form 4 lists a transaction in which 13,219 shares of common stock were disposed of at a price of
The filing also reports additional indirect holdings of common stock attributed to Mr. Treace’s spouse and various trusts, with share amounts of 1,605,000, 1,471,250, 1,839,063, and 408,816. The reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts she controls, as well as shares held in trusts for which he serves as trustee or co‑trustee.
Treace Medical Concepts reported that it has released certain preliminary unaudited financial results for the quarter and year ended December 31, 2025. These results are shared through a press release furnished as an exhibit and are not treated as formally filed financial statements. The company also posted an updated investor presentation on its investor relations website.
Treace plans to use this presentation in meetings with analysts and investors, including at the J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. A live webcast of this event, along with an archived recording and the presentation, will be available in the Investors section of the company’s website.
Treace Medical Concepts entered into new 60‑month credit facilities consisting of a term loan agreement with SLR Investment Corp. providing up to
The loans are secured by substantially all company assets and include a minimum liquidity requirement under which cash and cash equivalents in controlled accounts must exceed
Treace Medical Concepts (TMCI) reported Q3 2025 results. Revenue was $50.2 million, up 11.4% year over year, as more bunion procedure kits were sold, partly offset by lower average selling prices on newer systems. Gross profit was $39.7 million. Operating expenses were $55.4 million, leading to a net loss of $16.3 million, or $0.26 per share.
For the first nine months of 2025, revenue reached $150.2 million and net loss was $49.6 million, or $0.79 per share. As of September 30, 2025, cash and cash equivalents were $7.7 million and marketable securities were $49.7 million. Total principal outstanding under the term and revolving loans was $54.0 million. Stockholders’ equity was $89.2 million. Shares outstanding were 63,718,073 as of October 31, 2025.
Management noted continued adoption of minimally invasive osteotomy solutions and competitive pressures, which have reduced average selling prices even as kit volumes increased.
Treace Medical Concepts (TMCI) furnished its Q3 2025 results via a press release attached as Exhibit 99.1. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company also announced a board change. Richard W. Mott retired from the Board on November 3, 2025, for personal reasons and not due to any disagreement. On November 5, 2025, the Board reduced its size from eight to seven members; there are currently no vacancies.
Treace Medical Concepts (TMCI) reported an insider transaction on a Form 4. On 10/24/2025, the Chief Innovation Officer recorded a transaction in Common Stock with code F for 208 shares at $0, marked as a disposition. Following the transaction, the officer beneficially owns 373,599 shares, which includes 283,948 restricted stock units. Ownership is reported as direct.
Treace Medical Concepts (TMCI) reported an insider Form 4 for its Chief Legal & Compliance Officer and Corporate Secretary. On 10/25/2025, the filer disposed of 984 shares of common stock at $0 under transaction code F. Following the transaction, the filer beneficially owned 548,281 shares directly. A footnote states this figure includes 426,170 restricted stock units.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 6,260,000 shares of Treace Medical Concepts, Inc., representing 9.91% of the outstanding common stock based on 63,173,126 shares outstanding as of July 31, 2025. The reported position is held directly by Armistice Capital Master Fund Ltd. with Armistice Capital acting as investment manager and Steven Boyd as managing member. The Reporting Persons disclaim sole voting or dispositive power; all voting and dispositive power is reported as shared (6,260,000 shares). The Master Fund is identified as the direct holder and retains rights to dividends or sale proceeds.
FAQ
What is the current stock price of Treace Medical Concepts (TMCI)?
What is the market cap of Treace Medical Concepts (TMCI)?
